Homology Medicines, Inc. QTTB 深 滬
等待開盤 04-30 09:30:00 美东时间
5.50
-0.220
-3.85%
華盛通- 最 高5.88
- 今 開5.72
- 成交量 14.75万股
- 最 低 5.38
- 昨 收 5.72
- 總市值 8046.20万
- 52周最高 8.045
- 市盈率 靜 2.27
- 換手率 1.01%
- 52周最低 1.345
- 委 比 74.69%
- 總股本 1462.95万
- 歷史最高 572.40
- 量 比 0.48
- 振 幅 8.74%
- 歷史最低 1.345
- 每 手 1
- 風險率 1.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the company for $11.75 billion, $2 higher than current price.
04-27 16:45
美股夜盘 | Homology Medicines, Inc.跌20.58%，最新股价4.94美元
Homology Medicines, Inc.跌20.58%，报4.94美元
04-27 10:01
美股夜盘 | Aditxt, Inc.涨34.85%，Intellia Therapeutics, Inc.涨24.21%
Cheetah Net Supply Chain Service, Inc. Class A涨-24.71%；香颂国际涨-17.80%；Homology Medicines, Inc.涨-13.02%
04-27 08:05
Q32 Bio Files Prospectus To Launch New $75M At-The-Market Offering Program
As previously disclosed, on March 27, 2026, Q32 Bio Inc. (the "Company") entered into a Controlled Equity OfferingSM Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. (the "Sales Agent"),
04-25 04:12
Q32 Bio Files Prospectus To Offer And Sell Common Stock Up To $14.2M Through Cantor
-SEC Filing
03-28 05:25
Q32 Bio shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.
Q32 Bio shares are trading higher after the company reported better-than-expect...
03-11 01:15
Q32 Bio Q4 Adj. EPS $3.65 Beats $(0.98) Estimate, Sales $53.737M
Q32 Bio (NASDAQ:QTTB) reported quarterly earnings of $3.65 per share which beat the analyst consensus estimate of $(0.98) by 473.98 percent. This is a 414.66 percent increase over losses of $(1.16) per share from the
03-10 19:26
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
HC Wainwright & Co. Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $13
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Buy rating and announces Price Target of $13.
02-25 20:04
Market-Moving News for December 1st
QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties DYAI: 35% | Dyadic
2025-12-01 20:37
